Yahoo
NSE - Delayed Quote INR

Acutaas Chemicals Limited (ACUTAAS.NS)

4,003.60 +26.90 (+0.68%)
At close: October 30 at 3:29:53 PM GMT+5:30
Chart Range Bar
Loading chart for ACUTAAS.NS
  • Previous Close 3,976.70
  • Open 3,963.00
  • Bid --
  • Ask --
  • Day's Range 3,906.20 - 4,024.00
  • 52 Week Range 1,570.00 - 4,032.20
  • Volume 1,147,501
  • Avg. Volume 486,273
  • Market Cap (intraday) 327.779B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 74.95
  • EPS (TTM) 53.42
  • Earnings Date --
  • Forward Dividend & Yield 2.50 (0.06%)
  • Ex-Dividend Date Sep 17, 2026
  • 1y Target Est 3,551.67

Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients, as well as new chemical entities. It also provides specialty chemicals, including photoresist chemicals for semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.

www.acutaas.com

1,007

Full Time Employees

March 31

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

ACUTAAS.NS
135.00%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

ACUTAAS.NS
135.20%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

ACUTAAS.NS
593.76%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

ACUTAAS.NS
688.14%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 4.37B
Earnings 1.25B
Profit Margin 28.65%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
1B
2B
3B
4B
24.0%
26.0%
28.0%
30.0%

Analyst Insights

View More

Analyst Price Targets

1,783.00 Low
3,551.67 Average
4,003.60 Current
4,400.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.91%

  • Return on Assets (ttm)

    17.97%

  • Return on Equity (ttm)

    26.11%

  • Revenue (ttm)

    15.74B

  • Net Income Avi to Common (ttm)

    4.39B

  • Diluted EPS (ttm)

    53.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.07B

  • Total Debt/Equity (mrq)

    0.79%

  • Levered Free Cash Flow (ttm)

    -434.9M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: